Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPK inhibition to restore radioiodine uptake in radioiodine-refractory thyroid cancer
2016-002941-49Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib and dabrafenib + trametinib in thyroid cancer (2 cohorts), sponsored by Universitätsmedizin Essen. Started Jul 2016; status: completed.
02
Drugs
trametinibdabrafenib + trametinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on 2016-002941-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002941-49.